Skip to main content

Table 4 Analysis of cancer specific survival (CSS) in RCC, patients with metastases

From: Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

  Univariate Analysis Multivariate Analysis
Variable HR 95% CI p HR 95% CI p
Grading 2 vs. 1 0.59 0.24-1.44 0.247 0.65 0.25-1.74 0.395
Grading 3/4 vs. 1 1.03 0.43-2.45 0.950 1.18 0.47-3.01 0.725
Karnofsky < 80 vs. ≥ 80 1.90 0.99-3.64 0.054 2.24 0.99-5.05 0.052
Age ≥ 65 years vs. < 65 years 1.39 0.84-2.31 0.202 1.47 0.79-2.73 0.228
Sex (Male vs. Female) 1.28 0.75-2.19 0.372 1.35 0.74-2.45 0.331
Clear cell RCC vs. non clear cell RCC 0.59 0.25-1.38 0.223 0.36 0.15-0.88 0.025
Nuclear EZH2 1-5% vs. 0% 2.18 0.95-5.00 0.065 2.63 1.03-6.71 0.043
Nuclear EZH2 >5-25% vs. 0% 2.92 1.22-6.97 0.016 3.35 1.29-8.74 0.013
Nuclear EZH2 >25-50% vs. 0% 3.91 1.51-10.16 0.005 4.92 1.72-14.10 0.003
Nuclear EZH2 >50% vs. 0% 0.98 0.25-3.91 0.978 0.70 0.13-3.75 0.677